Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Aurinia Pharmaceuticals Inc stock logo
AUPH
Aurinia Pharmaceuticals
$15.19
-0.2%
$15.42
$7.28
$16.88
$1.96B1.441.18 million shs893,220 shs
ImmunityBio, Inc. stock logo
IBRX
ImmunityBio
$7.92
+9.7%
$7.72
$1.95
$12.43
$7.56B0.0213.07 million shs19.04 million shs
Immunovant, Inc. stock logo
IMVT
Immunovant
$33.83
-0.9%
$27.19
$13.79
$36.28
$7.01B0.72.43 million shs1.88 million shs
Qiagen N.V. stock logo
QGEN
Qiagen
$35.47
+0.9%
$37.96
$32.53
$57.81
$7.25B0.642.57 million shs1.53 million shs
7 Stocks to Ride The A.I. Megaboom Cover


We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

  1. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
  2. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
  3. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply click the link below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Aurinia Pharmaceuticals Inc stock logo
AUPH
Aurinia Pharmaceuticals
-0.20%-2.32%-4.94%+5.27%+88.00%
ImmunityBio, Inc. stock logo
IBRX
ImmunityBio
+9.70%+2.06%+6.45%-16.98%+213.04%
Immunovant, Inc. stock logo
IMVT
Immunovant
-0.94%+28.68%+18.37%+24.24%+133.96%
Qiagen N.V. stock logo
QGEN
Qiagen
+0.68%+3.51%-7.59%-27.10%-19.90%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Aurinia Pharmaceuticals Inc stock logo
AUPH
Aurinia Pharmaceuticals
$15.19
-0.2%
$15.42
$7.28
$16.88
$1.96B1.441.18 million shs893,220 shs
ImmunityBio, Inc. stock logo
IBRX
ImmunityBio
$7.92
+9.7%
$7.72
$1.95
$12.43
$7.56B0.0213.07 million shs19.04 million shs
Immunovant, Inc. stock logo
IMVT
Immunovant
$33.83
-0.9%
$27.19
$13.79
$36.28
$7.01B0.72.43 million shs1.88 million shs
Qiagen N.V. stock logo
QGEN
Qiagen
$35.47
+0.9%
$37.96
$32.53
$57.81
$7.25B0.642.57 million shs1.53 million shs
7 Stocks to Ride The A.I. Megaboom Cover


We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

  1. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
  2. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
  3. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply click the link below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Aurinia Pharmaceuticals Inc stock logo
AUPH
Aurinia Pharmaceuticals
-0.20%-2.32%-4.94%+5.27%+88.00%
ImmunityBio, Inc. stock logo
IBRX
ImmunityBio
+9.70%+2.06%+6.45%-16.98%+213.04%
Immunovant, Inc. stock logo
IMVT
Immunovant
-0.94%+28.68%+18.37%+24.24%+133.96%
Qiagen N.V. stock logo
QGEN
Qiagen
+0.68%+3.51%-7.59%-27.10%-19.90%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Aurinia Pharmaceuticals Inc stock logo
AUPH
Aurinia Pharmaceuticals
2.33
Hold$17.2513.56% Upside
ImmunityBio, Inc. stock logo
IBRX
ImmunityBio
2.71
Moderate Buy$14.2079.29% Upside
Immunovant, Inc. stock logo
IMVT
Immunovant
2.45
Hold$37.3310.36% Upside
Qiagen N.V. stock logo
QGEN
Qiagen
2.50
Moderate Buy$44.9826.81% Upside

Current Analyst Ratings Breakdown

Latest AUPH, IBRX, QGEN, and IMVT Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/26/2026
Immunovant, Inc. stock logo
IMVT
Immunovant
Boost Price TargetBuy$44.00 ➝ $62.00
5/22/2026
Immunovant, Inc. stock logo
IMVT
Immunovant
Boost Price TargetHold$23.00 ➝ $30.00
5/21/2026
Immunovant, Inc. stock logo
IMVT
Immunovant
Reiterated RatingBuy
5/21/2026
Immunovant, Inc. stock logo
IMVT
Immunovant
Boost Price TargetBuy$35.00 ➝ $40.00
5/21/2026
Immunovant, Inc. stock logo
IMVT
Immunovant
Boost Price TargetBuy$32.00 ➝ $43.00
5/21/2026
ImmunityBio, Inc. stock logo
IBRX
ImmunityBio
Reiterated RatingBuy$12.00
5/20/2026
ImmunityBio, Inc. stock logo
IBRX
ImmunityBio
Reiterated RatingBuy$15.00
5/18/2026
Qiagen N.V. stock logo
QGEN
Qiagen
Set Price TargetHold$50.00 ➝ $36.00
5/18/2026
Qiagen N.V. stock logo
QGEN
Qiagen
Reiterated RatingHold
5/15/2026
Aurinia Pharmaceuticals Inc stock logo
AUPH
Aurinia Pharmaceuticals
DowngradeBuy (B-)Hold (C+)
5/12/2026
Qiagen N.V. stock logo
QGEN
Qiagen
DowngradeHold (C)Hold (C-)
(Data available from 5/27/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Aurinia Pharmaceuticals Inc stock logo
AUPH
Aurinia Pharmaceuticals
$283.05M6.90$1.01 per share15.02$4.41 per share3.44
ImmunityBio, Inc. stock logo
IBRX
ImmunityBio
$113.29M73.22N/AN/A($0.83) per share-9.54
Immunovant, Inc. stock logo
IMVT
Immunovant
N/AN/AN/AN/A$4.15 per shareN/A
Qiagen N.V. stock logo
QGEN
Qiagen
$2.10B3.48$3.43 per share10.33$16.17 per share2.19
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Aurinia Pharmaceuticals Inc stock logo
AUPH
Aurinia Pharmaceuticals
$287.20M$2.177.0018.99N/A99.97%26.62%19.65%7/30/2026 (Estimated)
ImmunityBio, Inc. stock logo
IBRX
ImmunityBio
-$351.40M-$0.85N/AN/AN/A-606.15%N/A-59.53%8/4/2026 (Estimated)
Immunovant, Inc. stock logo
IMVT
Immunovant
-$505.61M-$2.78N/AN/AN/AN/A-65.66%-59.88%8/10/2026 (Estimated)
Qiagen N.V. stock logo
QGEN
Qiagen
$424.88M$1.9118.5213.333.5019.16%14.40%8.40%8/4/2026 (Estimated)

Latest AUPH, IBRX, QGEN, and IMVT Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/20/2026Q4 2026
Immunovant, Inc. stock logo
IMVT
Immunovant
-$0.60-$0.73-$0.13-$0.73N/AN/A
5/7/2026Q1 2026
Aurinia Pharmaceuticals Inc stock logo
AUPH
Aurinia Pharmaceuticals
$0.18$0.25+$0.07$0.25$76.98 million$77.71 million
5/7/2026Q1 2026
ImmunityBio, Inc. stock logo
IBRX
ImmunityBio
-$0.08-$0.62-$0.54-$0.62$43.07 million$44.21 million
5/7/2026Q1 2026
Qiagen N.V. stock logo
QGEN
Qiagen
$0.54$0.54N/A$0.33$496.15 million$492.32 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Aurinia Pharmaceuticals Inc stock logo
AUPH
Aurinia Pharmaceuticals
N/AN/AN/AN/AN/A
ImmunityBio, Inc. stock logo
IBRX
ImmunityBio
N/AN/AN/AN/AN/A
Immunovant, Inc. stock logo
IMVT
Immunovant
N/AN/AN/AN/AN/A
Qiagen N.V. stock logo
QGEN
Qiagen
$0.350.99%N/A18.32%N/A

Latest AUPH, IBRX, QGEN, and IMVT Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
5/11/2026
Qiagen N.V. stock logo
QGEN
Qiagen
annual$0.351.04%7/7/20267/7/20267/14/2026
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Aurinia Pharmaceuticals Inc stock logo
AUPH
Aurinia Pharmaceuticals
0.08
5.55
5.01
ImmunityBio, Inc. stock logo
IBRX
ImmunityBio
N/A
6.67
6.66
Immunovant, Inc. stock logo
IMVT
Immunovant
N/A
9.09
9.09
Qiagen N.V. stock logo
QGEN
Qiagen
0.49
3.21
2.57

Institutional Ownership

CompanyInstitutional Ownership
Aurinia Pharmaceuticals Inc stock logo
AUPH
Aurinia Pharmaceuticals
36.83%
ImmunityBio, Inc. stock logo
IBRX
ImmunityBio
8.58%
Immunovant, Inc. stock logo
IMVT
Immunovant
47.08%
Qiagen N.V. stock logo
QGEN
Qiagen
70.00%

Insider Ownership

CompanyInsider Ownership
Aurinia Pharmaceuticals Inc stock logo
AUPH
Aurinia Pharmaceuticals
12.20%
ImmunityBio, Inc. stock logo
IBRX
ImmunityBio
69.48%
Immunovant, Inc. stock logo
IMVT
Immunovant
1.80%
Qiagen N.V. stock logo
QGEN
Qiagen
9.00%
CompanyEmployeesShares OutstandingFree FloatOptionable
Aurinia Pharmaceuticals Inc stock logo
AUPH
Aurinia Pharmaceuticals
300128.60 million112.91 millionOptionable
ImmunityBio, Inc. stock logo
IBRX
ImmunityBio
5901.05 billion319.65 millionOptionable
Immunovant, Inc. stock logo
IMVT
Immunovant
120205.31 million201.61 millionOptionable
Qiagen N.V. stock logo
QGEN
Qiagen
5,654206.08 million187.53 millionOptionable

Recent News About These Companies

Barclays Remains a Hold on Qiagen (QGEN)

New MarketBeat Followers Over Time

Media Sentiment Over Time

Aurinia Pharmaceuticals stock logo

Aurinia Pharmaceuticals NASDAQ:AUPH

$15.19 -0.03 (-0.20%)
Closing price 05/26/2026 04:00 PM Eastern
Extended Trading
$15.27 +0.08 (+0.51%)
As of 07:04 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company was incorporated in 1993 and is headquartered in Edmonton, Canada.

ImmunityBio stock logo

ImmunityBio NASDAQ:IBRX

$7.92 +0.70 (+9.70%)
Closing price 05/26/2026 04:00 PM Eastern
Extended Trading
$7.92 +0.00 (+0.06%)
As of 07:23 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

ImmunityBio, Inc., a clinical-stage biotechnology company, engages in developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins; DNA, RNA, and recombinant protein vaccines; and cell therapies. The company's platforms have generated therapeutic agents that are currently being or planned to be studied in clinical trials across various indications in liquid and solid tumors, including bladder, lung and colorectal cancers, and glioblastoma multiforme. Its lead biologic product candidate is Anktiva, an FDA-approved immunotherapy in combination with bacillus calmette-guérin (BCG) for the treatment of adult patients with BCG unresponsive non-muscle invasive bladder cancer with carcinoma in situ, with or without papillary tumors. The company has collaboration agreements with National Cancer Institute. It also has license agreements with 3M Innovative Properties Company; Access to Advanced Health Institute; LadRx Corporation; Sanford Health; Shenzhen Beike Biotechnology Co. Ltd.; Viracta Therapeutics, Inc.; and GlobeImmune, Inc. The company is based in San Diego, California.

Immunovant stock logo

Immunovant NASDAQ:IMVT

$33.83 -0.32 (-0.94%)
Closing price 05/26/2026 04:00 PM Eastern
Extended Trading
$34.25 +0.42 (+1.24%)
As of 07:17 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that target the neonatal fragment crystallizable receptor for the treatment of myasthenia gravis, thyroid eye disease, chronic inflammatory demyelinating polyneuropathy, and Graves diseases, as well as warm autoimmune hemolytic anemia. The company is headquartered in New York, New York. Immunovant, Inc. operates as a subsidiary of Roivant Sciences Ltd.

Qiagen stock logo

Qiagen NYSE:QGEN

$35.47 +0.30 (+0.85%)
Closing price 05/26/2026 03:58 PM Eastern
Extended Trading
$36.04 +0.58 (+1.62%)
As of 07:15 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials. The firm assay technologies make these biomolecules visible and ready for analysis. Its bioinformatics software and knowledge bases interpret data to report relevant, actionable insights. The company was founded by Detlev H. Riesner and Metin Colpan on April 29, 1996, and is headquartered in Venlo, the Netherlands.